Clinical trials: Hypercytokinemia
Febrile Neutropenia
Remote Temperature Monitoring of Adult Subjects Undergoing Outpatient Stem Cell Transplant or CAR-T Cell Therapy
IDION is currently seeking FDA approval for this device- the IDION iTempShield. It is a skin-safe, FDA complaint and non-invasive device that can read and monitor skin temperature.
- Trial name
- NCT05576220
- Testing
- IDION iTempShield
- Where
- United States
- Volunteers
- 210 people
- Sponsor
- IDION Inc.
COVID-19 Drug Treatment
Sarilumab Treatment In cytoKinE Storm Caused by Infection With COVID-19
Phase II, one-arm, open label, multicentric study, to evaluate treatment of severe COVID-19 with sarilumab prior to entry into the intensive care unit (ICU).
- Trial name
- STRIKESARS (NCT04661527)
- Testing
- Sarilumab
- Where
- 2 sites in Spain
- Volunteers
- 60 people
- Sponsor
- Clinica Universidad de Navarra, Universidad de Navarra
Non-Hodgkin Lymphoma, Cytokine Release Syndrome
Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab
The goal of this clinical trial is to is to determine the safety, feasibility and efficacy of siltuximab prophylaxis of cytokine release syndrome and neurotoxicity occurring after epcoritamab subcutaneous administration for…
- Trial name
- NCT06447376
- Testing
- Siltuximab, Epcoritamab, Gemcitabine and oxaliplatin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Taylor Brooks
COVID 19
Oral 25-hydroxyvitamin D3 and COVID-19
The goal of this clinical trial is to investigate the therapeutic efficacy of rapidly correcting vitamin D deficiency in adults with the use of 25-hydroxyvitamin D3 [25(OH)D3] for reducing the risk of acquiring the SARS-CoV-2…
- Trial name
- NCT04386850
- Testing
- Oral 25-Hydroxyvitamin D3
- Where
- Iran
- Volunteers
- 1,500 people, healthy volunteers welcome
- Sponsor
- Tehran University of Medical Sciences
COVID-19, Cytokine Storm
CORONA: A Study Using DeltaRex-G Gene Therapy for Symptomatic COVID-19
COVID-19 is an infectious disease caused by severe acute respiratory syndrome coronavirus 2. COVID-19 causes life threatening complications known as Cytokine Release Syndrome or Cytokine Storm and Acute Respiratory Distress…
- Conditions
- COVID-19, Cytokine Storm, Acute Respiratory Distress Syndrome
- Trial name
- CORONA (NCT04378244)
- Testing
- DeltaRex-G
- Sponsor
- Aveni Foundation
Septic Shock, Acute Respiratory Distress Syndrome
CytOSorb TreatMent Of Critically Ill PatientS Registry
Registry intended to provide a data repository and reporting infrastructure for the surveillance of CytoSorb device use in real-world critical care settings, and to serve as an objective, comprehensive, and scientifically-based…
- Conditions
- Septic Shock, Acute Respiratory Distress Syndrome, Trauma, Rhabdomyolysis
- Trial name
- COSMOS (NCT05146336)
- Testing
- CytoSorb
- Where
- 28 sites in Austria, Germany and 4 more
- Volunteers
- 3,000 people
- Sponsor
- CytoSorbents, Inc
Morbid Obesity, Opioid Use
Inflammatory Response to Opioid Versus Opioid Free Anesthesia
Anesthetic agents, including opioids can modulate the altered immune function in patients with obesity through mechanisms that involve the expression and release of cytokines.
- Conditions
- Morbid Obesity, Opioid Use, Fentanyl Adverse Reaction, Cytokine Storm
- Trial name
- NCT04854252
- Testing
- Fentanyl
- Where
- Mexico
- Volunteers
- 40 people
- Sponsor
- University of Guadalajara
COVID-19
Anti-inflammatory/Antioxidant Oral Nutrition Supplementation in COVID-19
COVID-19 pandemic threatens patients, societies and healthcare systems around the world. The host immunity determines the progress of the disease and its lethality.
- Trial name
- ONSCOVID19 (NCT04323228)
- Testing
- Oral supplement enriched in antioxidants
- Where
- Saudi Arabia
- Volunteers
- 40 people
- Sponsor
- King Saud University
Extensive-Stage Small Cell Lung Cancer
Real-World Use of Tarlatamab in Chinese Patients With Small-Cell Lung Cancer
This is an investigator-initiated, single-center, observational, noninterventional retrospective real-world cohort study evaluating the effectiveness and safety of tarlatamab as second-line or later-line therapy in Chinese adults…
- Trial name
- NCT07885332
- Testing
- Tarlatamab
- Where
- China
- Volunteers
- 26 people
- Sponsor
- Ruijin Hospital
Heart; Dysfunction Postoperative, Cardiac Surgery, Cytokine Release Syndrome
Peri-operative Prediction of Prolonged Stay in the Cardiac Intensive Care Unit for Adult Cardiac Surgery
The purpose of this study is to create a model using intra-operative modified SOFA score and peri-operative clinical factors to predict prolonged stay in the cardiac intensive care unit (CICU) for adult cardiac surgery with…
- Trial name
- NCT01559870
- Where
- 3 sites in Thailand
- Volunteers
- 164 people
- Sponsor
- Thepakorn Sathitkarnmanee
Relapsed/Refractory Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia (AML)
CLL-1-Targeted In Vivo CAR-T Cell Immunotherapy for Relapsed/Refractory Acute Myeloid Leukemia
This is a single-center, open-label, single-arm, phase 1 dose-escalation study to evaluate the safety, tolerability, preliminary efficacy, and cellular kinetics of SL1CC Injection, an in vivo CAR-T therapy targeting CLL-1, in…
- Trial name
- NCT07841002
- Testing
- SL1CC Injection
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Liping Dou
COVID-19
A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE)
Study KIN-1901-2001 is a multi-center, adaptive, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of gimsilumab in subjects with lung injury or acute respiratory distress syndrome (ARDS)…
- Trial name
- NCT04351243
- Testing
- Gimsilumab
- Where
- 33 sites in United States
- Volunteers
- 227 people
- Sponsor
- Kinevant Sciences GmbH
Covid-19, Cytokine Storm
Treatment of Severe COVID-19 Patients Using Secretome of Hypoxia-Mesenchymal Stem Cells in Indonesia
In this randomized controlled trial (RCT), severe cases of COVID-19 infection will be treated with secretome of hypoxia-mesenchymal stem cells.
- Trial name
- NCT04753476
- Testing
- Injection of Secretome-MSCs, Standard treatment of Covid-19
- Where
- 6 sites in Indonesia
- Volunteers
- 48 people
- Sponsor
- Stem Cell and Cancer Research Indonesia
Acute Respiratory Distress Syndrome, Inflammation
Dexmedetomidine to Improve Outcomes of ARDS in Critical Care COVID-19 Patients
A continuous infusion of Dexmedetomidine (DEX) will be administered to 80 patients admitted to Critical Care because of signs of Respiratory Insufficiency requiring non-invasive ventilation.
- Conditions
- Acute Respiratory Distress Syndrome, Inflammation, Dexmedetomidine, Cytokine Storm
- Trial name
- COVID-DEX (NCT04358627)
- Testing
- Dexmedetomidine Injectable Product
- Volunteers
- 80 people
- Sponsor
- Hospital Clinic of Barcelona
CRS - Cytokine Release Syndrome, HLH
Tadekinig Alfa (IL-18BP) Rescue Therapy for CAR T Cell Related Cytokine Release Syndrome (CRS) and HLH-like Syndrome
This is a pilot, open-label study to assess the safety and feasibility of using investigational drug(s) as rescue therapies for CAR T cell related CRS and HLH-like syndrome (CRHLS).
- Trial name
- NCT05306080
- Testing
- Tadekinig alfa (IL-18BP)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Pennsylvania
Cytokine Release Syndrome
Jafron Haemoadsorption During Cardiopulmonary Bypass
Cardiopulmonary bypass (CPB) is often associated with degrees of complex inflammatory response mediated by various cytokines. This response can, in severe cases, lead to systemic hypotension and organ dysfunction.
- Trial name
- JAFRONCPB (NCT05349669)
- Testing
- Jafron use during CPB
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- Anthea Hospital Bari
COVID-19 Acute Respiratory Distress Syndrome, Cytokine Release Syndrome
Safety and Effectiveness of Cyclosporin in the Management of COVID19 ARDS Patients in Alexandria University Hospital
The study to evaluate the effect of cyclosporine ( IL2 inhibitor and antiviral) verse standard care treatment on decrease ADRS, hyper inflammation, hypercytokinemia, and the mortality rate
- Conditions
- COVID-19 Acute Respiratory Distress Syndrome, Cytokine Release Syndrome, Pulmonary Fibrosis
- Trial name
- NCT04979884
- Testing
- cyclosporine
- Where
- Egypt
- Volunteers
- 66 people
- Sponsor
- Alexandria University
Cytokine Storm, COVID-19
Cytokine Storm Among Bangladeshi Patients With COVID-19
COVID -19, first reported in Wuhan, China, strikes the world hard as a pandemic by spreading up to 213 countries. Bangladesh is also facing its havoc with the death of 3000 among 229,185 cases at its 141st day.
- Trial name
- NCT04598334
- Where
- Bangladesh
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- International Centre for Diarrhoeal Disease Research, Bangladesh
COVID-19, Pneumonia
Low-Dose Radiation Therapy to Lungs in Moderate COVID-19 Pneumonitis: A Case-Control Pilot Study
This pilot case-control study at Mahatma Gandhi Institute of Medical Sciences (MGIMS), Sevagram, India is designed to evaluate the use of low dose radiotherapy (LDRT) in patients with moderate COVID-19 with specific objectives to…
- Trial name
- LOCORAD (NCT04904783)
- Testing
- Low dose radiotherapy
- Where
- 2 sites in India
- Volunteers
- 20 people
- Sponsor
- Mahatma Gandhi Institute of Medical Sciences
COVID-19, SARS-CoV2 Infection
Effect of IMMUNEPOTENT-CRP on Serum Pro-Inflammatory Cytokines in Mild to Moderate COVID-19
In this study, the effects of IMMUNEPOTENT-CRP (I-CRP), a dialyzable leukocyte extract (DLE) derived from bovine spleen cells, on the levels of key inflammatory cytokines in outpatients with COVID-19 were examined.
- Trial name
- ICRPDLECOVID (NCT06676709)
- Testing
- IMMUNEPOTENT-CRP (I-CRP)
- Where
- 2 sites in Mexico
- Volunteers
- 80 people
- Sponsor
- Universidad Autonoma de Nuevo Leon